January 2023
Dr. Sofie Derijcke discusses the key results of the UNICORN study, assessing osimertinib in advanced NSCLC patients with uncommon activating EGFR mutations (Dutch)
In this episode, Dr. Sofie Derijcke (AZ Groeninge, Kortrijk) discusses the key results of the UNICORN study, assessing osimertinib in advanced non-small cell lung cancer (NSCLC) patients with uncommon activating EGFR mutations (Dutch).
This OncoTalk is brought to you by BJMO in partnership with AstraZeneca Belgium & Luxemburg.
NS ID XL-3147-Revision date 01/2023-WEB Local code 89
SmPC osimertinib
